Predict your next investment

See what CB Insights has to offer

Investments

1

Portfolio Exits

1

About Prof. Riesner

Prof. Riesner is a co-founder of QIAGEN. He has been on the Company's Supervisory Board since 1984 and was appointed Chairman of the Supervisory Board in 1999. Prof. Riesner has held the Chair of Biophysics at the Heinrich-Heine-University in Düsseldorf since 1980. In 1996, he was also appointed to the position of Vice President of Research, and in 1999, he was nominated Director of Technology at the University of Düsseldorf. Prior to that he was Professor of Biophysical Chemistry at the Darmstadt Institute of Technology and from 1975 to 1977, Lecturer of Biophysical Chemistry at Hannover Medical School. He has held guest professorships at the Institute of Microbiology, Academia Sinica, Beijing, and the Department of Neurology at the University of California, San Francisco. He received his M.S. in Physics from Hannover Institute of Technology and his Ph.D. from the University of Braunschweig, with post-graduate work at Princeton University. Professor Riesner is also a member of the supervisory board or a director of New Lab Bioquality, Erkrath; Therascope, Heidelberg; Kourion, Düsseldorf; Neuraxo, Düsseldorf; and Solutas Hürth.

Prof. Riesner Headquarters Location

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Prof. Riesner News

evocatal Closes €3.5M Series B Funding

Jun 27, 2013

By FinSMEs evocatal GmbH , a Düsseldorf, Germany-based enzyme specialist, closed a €3.5m Series B funding round. Backers included existing investors Roland Oetker, High-Tech Gründerfonds (HTGF) , Sirius Seedfonds Düsseldorf (SSFD) and business angel Prof. Riesner and new investors Nrw.Bank and Lanxess . The company intends to use the funds to extend its technology platform as well as its product portfolio. Led by CEO Dr. Thorsten Eggert, evocatal develops and produces enzymes and fine chemicals for the chemicals and pharmaceuticals industries. Its biocatalysts are employed for the synthesis of pharmaceutical compounds and chemical intermediates, as well as in the production of consumer goods – for example in the manufacture and refinement of textiles, adhesives, detergents and cosmetics. FinSMEs

Prof. Riesner Investments

1 Investments

Prof. Riesner has made 1 investments. Their latest investment was in evoxx technologies as part of their Series A on July 7, 2010.

CBI Logo

Prof. Riesner Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/5/2010

Series A

evoxx technologies

$2.64M

Yes

Date

7/5/2010

Round

Series A

Company

evoxx technologies

Amount

$2.64M

New?

Yes

Co-Investors

Sources

Prof. Riesner Portfolio Exits

1 Portfolio Exit

Prof. Riesner has 1 portfolio exit. Their latest portfolio exit was evoxx technologies on July 27, 2017.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/27/2017

Acquired

$99M

2

Date

7/27/2017

Exit

Acquired

Companies

Valuation

$99M

Acquirer

Sources

2

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.